|
肾素–血管紧张素–醛固酮系统对胰岛素分泌的调节作用
|
Abstract:
[1] | L. Guariguata. By the numbers: New estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Research and Clinical Practice, 2012, 98(3): 524-525. |
[2] | R. Saxena, B. F. Voight, V. Lyssenko, et al. Genome-wide asso- ciation analysis identifies loci for type 2 diabetes and triglyc- eride levels. Science, 2007, 316(5829): 1331-1336. |
[3] | R. Sladek, G. Rocheleau, J. Rung, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007, 445(7130): 881-885. |
[4] | S. E. Kahn, R. L. Hull, K. M. Utzschneider. Mechanisms linking obesity to insulin resistance and Type 2 diabetes. Nature, 2006, 444(7121): 840-846. |
[5] | C. Weyer, C. Bogardus, D. M. Mott, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pa- thogenesis of type 2 diabetes mellitus. Journal of Clinical Inves- tigation, 1999, 104(6): 787-794. |
[6] | P. S. Leung. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: Novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabetic Medicine, 2007, 24(2): 110-116. |
[7] | A. J. Scheen. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes & Metabolism, 2004, 30(6): 487-496. |
[8] | P. C. Underwood, G. K. Adler. The renin angiotensin aldosterone system and insulin resistance in humans. Current Hypertension Reports, 2013, 15(1): 59-70. |
[9] | S. M. Bindom, C. P. Hans, H. Xia, et al. Angiotensin I-con- verting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes, 2010, 59(10): 2540-2548. |
[10] | M. J. Niu, J. K. Yang, S. S. Lin, et al. Loss of angiotensin-con- verting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine, 2008, 34(1-3): 56-61. |
[11] | E. Fischer, C. Adolf, A. Pallauf, et al. Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. The Journal of Clinical Endocrinology & Metabolism, 2013, 98(6): 2513-2520. |
[12] | J. M. Luther, P. Luo, M. T. Kreger, et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia, 2011, 54(8): 2152-2163. |
[13] | D. W. Lambert, N. E. Clarke and A. J. Turner. Not just angiotensinases: New roles for the angiotensin-converting enzymes. Cellular and Molecular Life Sciences, 2010, 67(1): 89-98. |
[14] | M. Donoghue, F. Hsieh, E. Baronas, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) con- verts angiotensin I to angiotensin 1-9. Circulation Research, 2000, 87(5): E1-E9. |
[15] | R. A. Santos, A. J. Ferreira. Angiotensin-(1-7) and the renin-an- giotensin system. Current Opinion in Nephrology and Hyperten- sion, 2007, 16(2): 122-128. |
[16] | M. C. Chappell, D. W. Jacobsen and E. A. Tallant. Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells. Peptides, 1995, 16(4): 741-747. |
[17] | M. C. Chappell, A. Millsted, D. I. Diz, et al. Evidence for an intrinsic angiotensin system in the canine pancreas. Journal of Hypertension, 1991, 9(8): 751-759. |
[18] | P. S. Leung, M. C. Chappell. A local pancreatic renin-angio- tensin system: Endocrine and exocrine roles. The International Journal of Biochemistry & Cell Biology, 2003, 35(6): 838-846. |
[19] | C. Tikellis, P. J. Wookey, R. Candido, et al. Improved islet morphology after blockade of the rennin-angiotensin system in the ZDF rat. Diabetes, 2004, 53(4): 989-997. |
[20] | P. F. Wong, S. S. Lee and W. T. Cheung. Immunohistochemical colocalization of type II angiotensin receptors with somatostatin in rat pancreas. Regulatory Peptides, 2004, 117(3): 195-205. |
[21] | M. Tahmasebi, J. R. Puddefoot, E. R. Inwang, et al. The tissue renin-angiotensin system in human pancreas. Journal of Endocrinology, 1999, 161(2): 317-322. |
[22] | D. Batlle, S. M. Jose and M. Ye. ACE2 and diabetes: ACE of ACEs? Diabetes, 2010, 59(12): 2994-2996. |
[23] | P. S. Leung. The physiology of a local renin-angiotensin system in the pancreas. The Journal of Physiology, 2007, 580(Pt1): 31-37. |
[24] | L. Yuan, X. Li, G. L. Xu, et al. Effects of renin-angiotensin system blockade on islet function in diabetic rats. Journal of Endocrinological Investigation, 2010, 33(1): 13-19. |
[25] | Y. Marcus, G. Shefer and N. Stern. Adipose tissue renin-angio- tensin-aldosterone system (RAAS) and progression of insulin resistance. Molecular and Cellular Endocrinology, 2012. |
[26] | Y. Qi, H. Li, V. Shenoy, et al. Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. Experimental Physiology, 2012, 97(1): 89-101. |
[27] | Q. Cheng, P. S. Leung. An update on the islet renin-angiotensin system. Peptides, 2011, 32(5): 1087-1095. |
[28] | P. F. Wong, S. S. Lee and W. T. Cheung. Immunohistochemical colocalization of type II angiotensin receptors with somatostatin in rat pancreas. Regulatory Peptides, 2004, 117(3): 195-205. |
[29] | P. S. Leung. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: Novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabetic Medicine, 2007, 24(2): 110-116. |
[30] | P. O. Carlsson, C. Berne and L. Jansson. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats. Diabetologia, 1998, 41(2): 127-133. |
[31] | T. Lau, P. O. Carlsson and P. S. Leung. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets[J]. Diabetologia, 2004,47(2):240-248. |
[32] | K. Y. Chu, P. S. Leung. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young Type 2 diabetic mice. Antioxidants & Redox Signaling, 2007, 9(7): 869- 878. |
[33] | A. Kuno, T. Yamada, K. Masuda, et al. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology, 2003, 124(4): 1010-1019. |
[34] | P. V. Ennezat, M. Berlowitz, E. H. Sonnenblick, et al. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Current Cardiology Reports, 2000, 2(3): 258-262. |
[35] | A. H. van den Meiracker, I. T. V. A. Man, P. J. Admiraal, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? Journal of Hypertension, 1992, 10(8): 803-812. |
[36] | J. Biollaz, H. R. Brunner, I. Gavras, et al. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. Journal of Cardiovascular Pharmacology, 1982, 4(6): 966-972. |
[37] | W. J. Bommer. Use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1. Preventive Cardiology, 2008, 11(3): 148-154. |
[38] | B. K. Cole, S. R. Keller, R. Wu, et al. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension, 2010, 55(3): 715-721. |
[39] | Z. Huang, L. Jansson and A. Sjoholm. Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats. Clinical Science (London), 2007, 112(1): 69-76. |
[40] | R. Rodriguez, J. A. Viscarra, J. N. Minas, et al. Angiotensin re- ceptor blockade increases pancreatic insulin secretion and de- creases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology, 2012, 153(4): 1684-1695. |
[41] | Y. Saitoh, W. Hongwei, H. Ueno, et al. Candesartan attenuates fatty acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Research and Clinical Practice, 2010, 90(1): 54-59. |
[42] | Q. Cheng, P. K. Law, M. de Gasparo, et al. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydro- xy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the an- giotensin II type 1 receptor antagonist valsartan [N-(1-oxopen- tyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. Journal of Pharmacology and Experimental Therapeutics, 2008, 327(3): 683-691. |
[43] | S. Bokhari, Z. Israelian, J. Schmidt, et al. Effects of angiotensin II type 1 receptor blockade on beta-cell function in humans. Diabetes Care, 2007, 30(1): 181. |
[44] | N. J. van der Zijl, C. C. Moors, G. H. Goossens, et al. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care, 2011, 34(4): 845-851. |
[45] | M. E. Cooper, C. Tikellis and M. C. Thomas. Preventing diabetes in patients with hypertension: One more reason to block the renin-angiotensin system. Journal of Hypertension, 2006, 24(1): S57-S63. |
[46] | J. R. Sowers, L. Raij, I. Jialal, et al. Angiotensin receptor blo- cker/diuretic combination preserves insulin responses in obese hypertensives. Journal of Hypertension, 2010, 28(8): 1761-1769. |
[47] | M. R. Hayden, J. R. Sowers. Pancreatic renin-angiotensin-al- dosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. Journal of the CardioMetabolic Syndrome, 2008, 3(3): 129-131. |
[48] | S. B. Gurley, A. Allred, T. H. Le, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. Journal of Clinical Investigation, 2006, 116(8): 2218-2225. |
[49] | L. S. Zisman, G. E. Meixell, M. R. Bristow, et al. Angiotensin-(1-7) formation in the intact human heart: In vivo depen- dence on angiotensin II as substrate. Circulation, 2003, 108(14): 1679-1681. |
[50] | G. Paizis, C. Tikellis, M. E. Cooper, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin con- verting enzyme 2. Gut, 2005, 54(12): 1790-1796. |
[51] | J. Selvaraj, S. Sathish, C. Mayilvanan, et al. Excess aldosterone- induced changes in insulin signaling molecules and glucose oxidation in gastrocnemius muscle of adult male rat. Molecular and Cellular Biochemistry, 2013, 372(1-2): 113-126. |
[52] | Y. Huan, S. Deloach, S. W. Keith, et al. Aldosterone and aldosterone: renin ratio associations with insulin resistance and blood pressure in African Americans. Journal of the American Society of Hypertension, 2012, 6(1): 56-65. |
[53] | S. J. Sherajee, Y. Fujita, K. Rafiq, et al. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32(2): 257-263. |
[54] | M. H. Weinberger, W. B. White, L. M. Ruilope, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. American Heart Journal, 2005, 150(3): 426-433. |
[55] | K. Swaminathan, J. Davies, J. George, et al. Spironolactone for poorly controlled hypertension in type 2 diabetes: Conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia, 2008, 51(5): 762-768. |
[56] | Y. Arase, F. Suzuki, Y. Suzuki, et al. Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. Journal of Medical Virology, 2009, 81(9): 1584- 1590. |